Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for RYTM

Stock NameRhythm Pharmaceuticals Inc
TickerRYTM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS76243J1051
LEI529900JPNWXQ8DPLA551

Show aggregate RYTM holdings

News associated with RYTM

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypotha - 2025-08-20 22:52:50
Chicago Partners Investment Group LLC Sells 186 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Chicago Partners Investment Group LLC reduced its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,510 shares of the company’s stock after selling 186 shares during the period. Chicago Partners Investment Group LLC’s holdings […] - 2025-08-13 05:18:50
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $91.93
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average rating of “Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts […] - 2025-08-04 02:26:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Holdings Lifted by Victory Capital Management Inc.
Victory Capital Management Inc. lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,326 shares of the company’s stock after acquiring an additional 174 shares during the […] - 2025-08-01 05:01:17
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to “Hold”
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. RYTM has been the subject of several other reports. Oppenheimer boosted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an […] - 2025-07-28 04:00:47
Bank of New York Mellon Corp Sells 1,661 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Bank of New York Mellon Corp reduced its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.1% in the first quarter, HoldingsChannel reports. The firm owned 146,585 shares of the company’s stock after selling 1,661 shares during the period. Bank of New York Mellon Corp’s holdings in Rhythm Pharmaceuticals were worth $7,765,000 at […] - 2025-07-23 04:34:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective lifted by Canaccord Genuity Group from $92.00 to $105.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 17.71% from the stock’s current price. Several […] - 2025-07-20 05:22:52
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells $308,222.75 in Stock
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CAO Christopher Paul German sold 3,817 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total transaction of $308,222.75. Following the transaction, the chief accounting officer directly owned 922 shares of the […] - 2025-07-14 06:10:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High Following Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $76.00 to $110.00. Oppenheimer currently has an outperform rating on the stock. Rhythm Pharmaceuticals traded as high as $89.05 and last traded at $89.00, with […] - 2025-07-11 02:50:53
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up prior to trading on Wednesday after Needham & Company LLC raised their price target on the stock from $72.00 to $95.00. The stock had previously closed at $65.14, but opened at $76.75. Needham & Company LLC currently has a buy rating on the […] - 2025-07-10 02:19:11
Wednesday's ETF Movers: XBI, COPX
In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.7% on the day. Components of that ETF showing particular strength include shares of Rhythm Pharmaceuticals, up about 31.3% and shares of Capricor Therapeutics, up about 12.3% on the da - 2025-07-09 13:28:39
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of “Buy” by Brokerages
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock […] - 2025-07-07 03:16:56
Avior Wealth Management LLC Acquires Shares of 4,589 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Avior Wealth Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 4,589 shares of the company’s stock, valued at approximately $243,000. Several other institutional investors and hedge funds have also bought and sold shares of the business. Assenagon Asset […] - 2025-06-24 04:52:55
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of “Buy” from Analysts
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […] - 2025-06-12 04:56:54
Analysts Forecast 16% Upside For The Holdings of SMLF
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:51:20
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 76,084 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 76,084 shares of the company’s stock, valued at approximately $4,259,000. A number of other hedge funds and other institutional investors have also added to or reduced their […] - 2025-06-02 05:36:58
Nuveen Asset Management LLC Sells 972 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Nuveen Asset Management LLC decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,903 shares of the company’s stock after selling 972 shares during […] - 2025-05-29 05:36:56
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,156 shares of the company’s stock after buying an additional 654 shares during […] - 2025-05-23 05:32:53
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $75.38
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on […] - 2025-05-23 04:30:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by BNP Paribas Financial Markets
BNP Paribas Financial Markets boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 491.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,249 shares of the company’s stock after purchasing an additional 70,824 shares during the period. BNP […] - 2025-05-14 06:42:59
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Comerica Bank
Comerica Bank lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 17,113 shares of the company’s stock after selling 447 shares during the period. Comerica Bank’s holdings in Rhythm Pharmaceuticals were worth $958,000 as of its most recent filing with the […] - 2025-05-13 06:00:54
Stifel Financial Corp Has $1.09 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Stifel Financial Corp decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,516 shares of the company’s stock after selling 326 shares during the quarter. Stifel Financial Corp’s holdings in […] - 2025-05-09 05:27:01
First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company’s stock after buying an additional 47,575 shares during the period. First Trust Advisors LP owned 0.19% of […] - 2025-04-30 06:01:00
Legal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the period. Legal & General […] - 2025-04-24 05:07:03
Invesco Ltd. Has $16.95 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Invesco Ltd. grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 14.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 302,846 shares of the company’s stock after purchasing an additional 38,429 shares during the period. Invesco Ltd.’s holdings in Rhythm Pharmaceuticals were worth $16,953,000 at the end of the […] - 2025-04-21 04:44:46
Trexquant Investment LP Takes $437,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Trexquant Investment LP bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,798 shares of the company’s stock, valued at approximately $437,000. A number of other large investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors […] - 2025-04-13 05:31:02
Rhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Buy at Bank of America
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm presently has a $63.00 price objective on the stock. Bank of America‘s price objective points to a […] - 2025-04-09 02:52:50
Norges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company’s stock, valued at approximately $11,512,000. Norges Bank owned approximately 0.33% […] - 2025-04-08 04:48:51
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target upped by Wells Fargo & Company from $80.00 to $91.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other research firms have also recently issued reports on RYTM. Morgan Stanley restated […] - 2025-04-08 02:52:50
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price gapped up before the market opened on Monday after Wells Fargo & Company raised their price target on the stock from $80.00 to $91.00. The stock had previously closed at $46.95, but opened at $48.33. Wells Fargo & Company currently has an overweight rating on […] - 2025-04-08 02:12:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RYTM holdings

DateNumber of RYTM Shares HeldBase Market Value of RYTM SharesLocal Market Value of RYTM SharesChange in RYTM Shares HeldChange in RYTM Base ValueCurrent Price per RYTM Share HeldPrevious Price per RYTM Share Held
2025-11-11 (Tuesday)43,178USD 4,311,755RYTM holding increased by 96287USD 4,311,7550USD 96,287 USD 99.86 USD 97.63
2025-11-10 (Monday)43,178RYTM holding increased by 110USD 4,215,468RYTM holding decreased by -104252USD 4,215,468110USD -104,252 USD 97.63 USD 100.3
2025-11-07 (Friday)43,068USD 4,319,720RYTM holding increased by 77953USD 4,319,7200USD 77,953 USD 100.3 USD 98.49
2025-11-06 (Thursday)43,068RYTM holding increased by 110USD 4,241,767RYTM holding decreased by -31265USD 4,241,767110USD -31,265 USD 98.49 USD 99.47
2025-11-05 (Wednesday)42,958USD 4,273,032RYTM holding decreased by -237128USD 4,273,0320USD -237,128 USD 99.47 USD 104.99
2025-11-04 (Tuesday)42,958RYTM holding increased by 111USD 4,510,160RYTM holding decreased by -363258USD 4,510,160111USD -363,258 USD 104.99 USD 113.74
2025-11-03 (Monday)42,847USD 4,873,418RYTM holding decreased by -857USD 4,873,4180USD -857 USD 113.74 USD 113.76
2025-10-31 (Friday)42,847USD 4,874,275RYTM holding increased by 83552USD 4,874,2750USD 83,552 USD 113.76 USD 111.81
2025-10-30 (Thursday)42,847RYTM holding increased by 555USD 4,790,723RYTM holding decreased by -25913USD 4,790,723555USD -25,913 USD 111.81 USD 113.89
2025-10-29 (Wednesday)42,292RYTM holding increased by 548USD 4,816,636RYTM holding increased by 80362USD 4,816,636548USD 80,362 USD 113.89 USD 113.46
2025-10-28 (Tuesday)41,744USD 4,736,274RYTM holding increased by 79731USD 4,736,2740USD 79,731 USD 113.46 USD 111.55
2025-10-27 (Monday)41,744USD 4,656,543RYTM holding increased by 45083USD 4,656,5430USD 45,083 USD 111.55 USD 110.47
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RYTM by Blackrock for IE00BYXG2H39

Show aggregate share trades of RYTM

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY110101.05096.100 96.595USD 10,625 69.11
2025-11-06BUY110 98.490* 68.80
2025-11-04BUY111112.660102.100 103.156USD 11,450 68.46
2025-10-30BUY555116.000110.450 111.005USD 61,608 67.76
2025-10-29BUY548113.890114.590 114.520USD 62,757 67.51
2025-10-22SELL-440109.170109.745 109.688USD -48,263 66.35 Loss of -19,071 on sale
2025-10-20BUY220112.390113.560 113.443USD 24,957 65.87
2025-10-17BUY549110.280111.720 111.576USD 61,255 65.63
2025-10-15BUY872109.350109.720 109.683USD 95,644 65.39
2025-10-03BUY77099.020102.790 102.413USD 78,858 64.97
2025-10-02BUY11097.23099.830 99.570USD 10,953 64.79
2025-09-30BUY220100.990103.070 102.862USD 22,630 64.39
2025-09-26BUY22099.160100.070 99.979USD 21,995 63.98
2025-09-25BUY22099.14099.600 99.554USD 21,902 63.78
2025-09-24BUY196.910100.000 99.691USD 100 63.58
2025-09-18BUY10998.54098.880 98.846USD 10,774 63.38
2025-09-17BUY33096.10097.895 97.715USD 32,246 63.19
2025-08-20SELL-44098.70098.910 98.889USD -43,511 62.31 Loss of -16,097 on sale
2025-07-30BUY44084.66087.090 86.847USD 38,213 61.16
2025-07-17SELL-22090.68092.080 91.940USD -20,227 59.57 Loss of -7,121 on sale
2025-07-16BUY36491.44092.135 92.066USD 33,512 59.36
2025-07-11SELL-87286.70090.360 89.994USD -78,475 58.77 Loss of -27,228 on sale
2025-07-07BUY32766.39066.830 66.786USD 21,839 58.25
2025-07-02BUY5,99566.92067.750 67.667USD 405,664 58.13
2025-06-20BUY1,11061.99062.360 62.323USD 69,179 58.11
2025-06-11BUY21064.84067.265 67.022USD 14,075 57.87
2025-06-10BUY21067.37067.740 67.703USD 14,218 57.80
2025-06-04SELL-10564.39566.510 66.299USD -6,961 57.53 Loss of -921 on sale
2025-04-23BUY10559.84061.780 61.586USD 6,467 56.19
2025-04-10SELL-84057.83059.160 59.027USD -49,583 55.75 Loss of -2,750 on sale
2025-04-08SELL-10557.73063.110 62.572USD -6,570 55.68 Loss of -724 on sale
2025-04-07SELL-10554.96055.900 55.806USD -5,860 55.69 Loss of -12 on sale
2025-04-04SELL-52546.95049.055 48.845USD -25,643 55.79 Profit of 3,646 on sale
2025-04-01BUY91850.00054.670 54.203USD 49,758 55.91
2025-03-31SELL-30952.97053.410 53.366USD -16,490 55.94 Profit of 796 on sale
2025-03-21BUY2,17752.04054.450 54.209USD 118,013 56.13
2025-03-14SELL-1,53650.97052.050 51.942USD -79,783 56.35 Profit of 6,772 on sale
2025-03-07SELL-19250.79052.350 52.194USD -10,021 56.82 Profit of 888 on sale
2025-03-04SELL-9653.22053.500 53.472USD -5,133 57.02 Profit of 340 on sale
2025-02-25BUY19251.03055.010 54.612USD 10,486 57.37
2025-02-19SELL-9658.00058.240 58.216USD -5,589 57.43 Loss of -76 on sale
2025-02-13BUY28857.56058.645 58.537USD 16,859 57.45
2025-02-12BUY9657.64057.700 57.694USD 5,539 57.45
2025-02-11BUY38457.58058.160 58.102USD 22,311 57.44
2024-12-30SELL-3,14156.34056.840 56.790USD -178,377 56.89 Profit of 316 on sale
2024-11-18SELL-1,57258.50058.640 58.626USD -92,160 53.69 Loss of -7,760 on sale
2024-11-08SELL-10567.33067.610 67.582USD -7,096 51.97 Loss of -1,639 on sale
2024-10-21SELL-10550.19052.000 51.819USD -5,441 0.00 Loss of -5,441 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RYTM

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1957,7580112,12451.5%
2025-09-1879,8290132,26760.4%
2025-09-1794,8110142,28166.6%
2025-09-1669,29420105,41865.7%
2025-09-1549,993495130,67538.3%
2025-09-1291,089428207,39843.9%
2025-09-11102,9764,654284,27736.2%
2025-09-10112,3345,431192,88758.2%
2025-09-0981,3160146,46755.5%
2025-09-08107,0710320,02633.5%
2025-09-0585,28221165,03251.7%
2025-09-0463,0341,268179,40635.1%
2025-09-0393,8564,725232,51740.4%
2025-09-02118,6501,127276,51542.9%
2025-08-2952,45933140,59437.3%
2025-08-2888,661500177,30150.0%
2025-08-2734,3700144,19823.8%
2025-08-2635,8953,580182,87719.6%
2025-08-2552,3220141,15037.1%
2025-08-22134,2853,024254,45152.8%
2025-08-21237,643249345,61868.8%
2025-08-20158,6851,343190,44983.3%
2025-08-1959,92517894,09263.7%
2025-08-1874,0303,694131,50656.3%
2025-08-1567,4484,106159,63542.3%
2025-08-1482,22850225,05436.5%
2025-08-13118,4926,021264,48344.8%
2025-08-1277,184326156,47949.3%
2025-08-11104,4521,770229,18145.6%
2025-08-08104,6203,964349,55229.9%
2025-08-07118,63422,554179,49866.1%
2025-08-06128,9260232,03455.6%
2025-08-05150,641988242,99862.0%
2025-08-04113,562539192,79058.9%
2025-08-01162,238522245,73666.0%
2025-07-31107,0600186,42657.4%
2025-07-3074,13323152,13548.7%
2025-07-2984,977139138,58461.3%
2025-07-2890,1653232,09738.8%
2025-07-2566,761574128,31052.0%
2025-07-2466,075215173,15038.2%
2025-07-23113,2810215,58752.5%
2025-07-2296,0670222,05943.3%
2025-07-2178,36017228,06834.4%
2025-07-1867,969252244,27127.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.